One-year results of aflibercept in vascularized pigment epithelium detachment due to neovascular AMD: a prospective study



To evaluate individualized intravitreal aflibercept regimens for treatment of neovascular age-related macular degeneration (nAMD)-related pigment epithelial detachment (PED).


This prospective, multicenter, nonrandomized study included 32 eyes with nAMD-related PED, treated with ranibizumab for ≥6 months. All patients received intravitreal aflibercept (2 mg/0.05 mL) at baseline (no loading phase) and subsequently treated pro re nata with monthly follow-up for 12 months. Outcome measures included visual acuity, central retinal thickness (CRT), PED height and area, and neovascular network size.


At 12 months, aflibercept improved mean best-corrected visual acuity compared with baseline values (p>0.05); 50% of patients displayed complete resolution of intraretinal and/or subretinal fluid. Compared with baseline, significant decreases were observed for mean CRT and PED height (both p<0.01).


Aflibercept appears to induce anatomical improvement for at least 12 months after conversion from ranibizumab in patients experiencing nAMD-related PED. Significant reductions in both mean PED height and CRT were observed, although these changes were not necessarily related to significantly improved visual acuity scores. However, larger patient cohorts are required to extend and validate our results, and increased study duration would allow exploration of the potential long-term benefits and challenges of prolonged aflibercept use.

Eur J Ophthalmol 2017; 27(1): 74 - 79




Daniele Veritti, Valentina Sarao, Mariacristina Parravano, Luis Arias, Monica Varano, Paolo Lanzetta

Article History


Financial support: The research for this paper was partially financially supported by Ministry of Health and Fondazione Roma. Medical writing support was provided by Samuel Cooper, PhD, of Inspired Science, London, UK.
Conflict of interest: None of the authors has conflict of interest with this submission.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.



  • Department of Medical and Biological Sciences-Ophthalmology, University of Udine, Udine - Italy
  • European Institute of Ocular Microsurgery (IEMO), Udine - Italy
  • Department of Ophthalmology, Fondazione G.B. Bietti-IRCCS, Rome - Italy
  • Department of Ophthalmology, University of Barcelona, Bellvitge University Hospital, Barcelona - Spain

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.